TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02630485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graceful Lifestyle Changes
Description: Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graceful Lifestyle Changes
Description: Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Myo-inositol
Description: Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
Study: NCT00981292

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EGCG
Description: Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG
Description: Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG
Description: Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
Study: NCT03873233

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evone ventilator and Tritube
Description: Fraction of Inspired Oxygen (FIO2) 0.3 Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 End Expiratory Pressure (EEP) at +5 cm H2O Flow: start with 10 L/min and adjusted along with the peak inspiratory pressure to produce a tidal volume of 6 mL/kg and End-Tidal CO2 35-40 mmHg
Study: NCT00107471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00981292

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical grade silica was utilized as placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical grade silica was utilized as placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical grade silica was utilized as placebo
Study: NCT04295668

Intervention type: BEHAVIORAL
Intervention: Usual care
Description: The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool ≥2).

Intervention type: BEHAVIORAL
Intervention: Prehabilitation
Description: i) Exercise training: Ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training and strength muscular training.~ii) Promotion of physical activity: Pedometer-based program using a physical activity tracker linked to a mobile app.~iv) Nutritional optimization: Recommendations of a healthy balanced diet or adapted to their digestive symptoms. Daily amount of protein intake will be close to 2 g•Kg-1•day-1.~iv) Smoking cessation: Use of both cognitive behavioral intervention and pharmacological therapy by varenicline or nicotine replacement therapies.~v) Cognitive behavioral therapy: Weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment.
Study: NCT04527666

Intervention type: DRUG
Intervention: Anticoagulation Agents
Description: Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
Study: NCT04285177

Intervention type: PROCEDURE
Intervention: Strabismus surgery
Description: Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy

Intervention type: PROCEDURE
Intervention: Strabismus surgery
Description: Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy

Intervention type: PROCEDURE
Intervention: Strabismus surgery
Description: Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy
Study: NCT01814189

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sumatriptan+Promethazine (SPr)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan+Promethazine (SPr)
Study: NCT02484040

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Two-week course of radiation
Description: 33 Gy in 10 fractions for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two-week course of radiation
Description: oral capecitabine, 825mg/m2, bid
Study: NCT00107471

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04488991

Intervention type: OTHER
Intervention: Cervical Cancer Rate
Description: In the end of the Research, we will compare cervical cancer rates between groups
Study: NCT02311582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw for research purposes
Description: * Phase II patients only~* Drawn prior to MLA or biopsy/surgical resection procedure, and immediately prior to each the first dose of MK-3475. Subsequently, research blood will be drawn at doses 2, 4, 6, 9, 18, 36, and at the end of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw for research purposes
Description: * Phase II patients only~* Drawn prior to MLA or biopsy/surgical resection procedure, and immediately prior to each the first dose of MK-3475. Subsequently, research blood will be drawn at doses 2, 4, 6, 9, 18, 36, and at the end of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical lymph node fine needle aspiration
Description: * Optional~* Time of surgical procedure and 6 weeks +/- 1 week after surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical lymph node fine needle aspiration
Description: * Optional~* Time of surgical procedure and 6 weeks +/- 1 week after surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical lymph node fine needle aspiration
Description: * Optional~* Time of surgical procedure and 6 weeks +/- 1 week after surgical procedure
Study: NCT04847505

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-TATE
Description: The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.
Study: NCT00952679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Lesion Localization Needles (interv)
Description: needles to locate sln in CT monitor guided by CT
Study: NCT02760199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-AMG211
Description: Injection of 89Zr-AMG211 for imaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 89-ZrAMG211 PET
Description: 89Zr-AMG211 PET scan(s).
Study: NCT01250405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
Study: NCT04488991

Intervention type: OTHER
Intervention: Cervical Cancer Rate
Description: In the end of the Research, we will compare cervical cancer rates between groups

Intervention type: OTHER
Intervention: Cervical Cancer Rate
Description: In the end of the Research, we will compare cervical cancer rates between groups
Study: NCT03833349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinning Class
Description: Spinning Class twice a week for six weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Class
Description: Yoga Class twice a week for six weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Class
Description: Dance Class twice a week for six weeks.
Study: NCT04142762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158
Description: ABI-H2158 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158
Description: ABI-H2158 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158
Description: ABI-H2158 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158
Description: ABI-H2158 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158
Description: ABI-H2158 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol / Levonorgestrel
Description: Ethinyl Estradiol / Levonorgestrel tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching oral contraceptive
Description: Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
Study: NCT04114773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCARF (Survivors of Cardiac Arrest Rehabilitation focused on Fatigue)
Description: The intervention will be delivered by a multidisciplinary team. There will be individual testing and feedback on physical capacity and cognitive ability. Group sessions will include education on the consequences of cardiac arrest, promotion of techniques to ameliorate these consequences, for example, increasing physical activity or energy conservation. Additional sessions will cover psychological reactions; family life; work life; intimacy; and existential considerations.~Participants will have a course information book with a physical activity training diary and problem-solving therapy worksheets to use at home for 12-weeks. They will receive one phone call from the clinical team during this period. The 2-day return stay will revisit the subjects from the first 5-day stay.~Participating survivors who have a relative that wishes to attend will be included in all the group sessions and individual feedback but will not take part in the physical capacity or cognitive ability tests.
Study: NCT01524809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
Study: NCT03491852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOOST Intervention
Description: A cognitive and behavioural group therapy designed to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis.
Study: NCT00628134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calfactant
Description: single inhaled dose by nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calfactant
Description: single inhaled dose by nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic saline
Description: single inhaled dose by nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic saline
Description: single inhaled dose by nebulizer
Study: NCT04323098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
Study: NCT01269827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: starch tablets
Description: Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
Study: NCT00740428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pregnants for receive the physical therapy guide
Description: pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
Study: NCT02871791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study: NCT02098148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT05103995

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, just observation

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, just observation

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, just observation

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, just observation
Study: NCT00608491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stepped pharmacologic care
Description: Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Description: All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
Study: NCT02705352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Treatment medication

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study: NCT01619527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
Study: NCT03442595

Intervention type: OTHER
Intervention: Intensive diabetes education and medication management
Description: Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
Study: NCT01126567

Intervention type: OTHER
Intervention: Sampling Rate
Description: Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.
Study: NCT00612781

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery (Hoya AF-1 [UY] YA-60BB)
Description: implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery (Hoya AF-1 [UV] VA-60BB lens)
Description: implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
Study: NCT02681640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-AE105
Description: One injection of 68Ga-NOTA-AE105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography PET/CT
Description: Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT